SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for DermTech, Inc. (DMTKQ) (CIK 0001651944) — Sep 14, 2020

DermTech, Inc. (DMTKQ) (CIK 0001651944)
Date: Sept. 14, 2020 · CIK: 0001651944 · Accession: 0000000000-20-008647

AI Filing Summary & Sentiment

File numbers found in text: 333-248657

Date
September 14, 2020
Author
Not clearly detected
Form
UPLOAD
Company
DermTech, Inc. (DMTKQ) (CIK 0001651944)

Letter

United States securities and exchange commission logo September 14, 2020 Kevin Sun Chief Financial Officer DermTech, Inc. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 Re:DermTech, Inc. Registration Statement on Form S-3 Filed September 8, 2020 File No. 333-248657 Dear Mr. Sun: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeremy Glaser

Show Raw Text
United States securities and exchange commission logo
September 14, 2020
Kevin Sun
Chief Financial Officer
DermTech, Inc.
11099 N. Torrey Pines Road, Suite 100
La Jolla, CA 92037
Re:DermTech, Inc.
Registration Statement on Form S-3
Filed September 8, 2020
File No. 333-248657
Dear Mr. Sun:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jeremy Glaser